Parkwood LLC’s UroGen Pharma URGN Stock Holding History

Parkwood LLC’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-27,694	Closed	-$500K	–	382
2017 Q2	$500K	Buy	+27,694	New	+$481K	0.07%	185

Other funds holding URGN

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

DSAM Partners London, United Kingdom $176M AUM 83.78% 1-Year Est. Return

Parkwood LLC's URGN Position: Q3 2017 in Review

Parkwood LLC sold out of UroGen Pharma (URGN) in Q3 2017, closing a stake of 27,694 shares — an estimated $500K sold.

Parkwood LLC first reported a position in URGN in Q2 2017 and held it in 1 quarter. The position peaked at $500K in Q2 2017. 31 funds tracked by Wall St. Rank hold URGN as of Q3 2017.

Parkwood LLC reported no remaining UroGen Pharma position as of Q3 2017 after selling out during the quarter.
Parkwood LLC sold 27,694 UroGen Pharma shares in Q3 2017, an estimated $500K.
Parkwood LLC first reported a position in UroGen Pharma in Q2 2017 and held it in 1 quarter.
Parkwood LLC's UroGen Pharma position peaked at $500K in Q2 2017.
31 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2017.

Based on Parkwood LLC's 13F filing for Q3 2017, filed 1 Nov 2017.